The activation of catecholamine receptors and their downstream pathways likely is not alone sufficient to trigger but rather only modulates tumor initiation and growth through multiple mechanisms that involve the sympathetic nervous system or the tumor initiating cells, the TME, and immune regulatory cells directly. This evidence concerns the gene ADRB2 and neoplasm.